A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel

Sponsor
Weill Medical College of Cornell University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03803332
Collaborator
United States Department of Defense (U.S. Fed)
208
1
2
52.8
3.9

Study Details

Study Description

Brief Summary

The purpose of this study is to compare two kinds of therapy for Posttraumatic Stress Disorder (PTSD): exposure therapy (ET) and Interpersonal Psychotherapy (IPT). The results of this study will allow us to see if IPT and ET are equally effective in treating PTSD due to Military Sexual Trauma, with the long-term goal of making PTSD treatment effective for as many people as possible.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Exposure Therapy
  • Behavioral: Interpersonal Psychotherapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
208 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Non-Inferiority Randomized Controlled Clinical Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Consequent to Military Sexual Trauma
Actual Study Start Date :
Mar 9, 2020
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Exposure Therapy

Participants receive 10 90-minute exposure therapy sessions for PTSD following the treatment procedures as outlined in the standard Prolonged Exposure therapy manual.

Behavioral: Exposure Therapy
Psychotherapy including imaginal and in vivo exposure for PTSD.
Other Names:
  • Prolonged Exposure
  • Active Comparator: Interpersonal Psychotherapy

    Participants receive 14 weekly 50-minute Interpersonal Psychotherapy sessions focused on the interpersonal sequelae of trauma in current daily life.

    Behavioral: Interpersonal Psychotherapy
    Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.

    Outcome Measures

    Primary Outcome Measures

    1. Difference in mean Clinician Administered PTSD Scale-5 (CAPS-5) score changes between the Exposure Therapy (ET) and Interpersonal Psychotherapy (IPT) treatment groups from baseline to post-treatment [Baseline, 15 weeks in the IPT condition, 11 weeks in the ET condition]

      The CAPS-5 is used for rating the severity of PTSD symptoms. Scores range from 0-80 with higher scores indicating greater PTSD severity

    2. Change in CAPS-5 scores from baseline to post-treatment for the ET treatment group [Baseline, 11 weeks]

      The CAPS-5 is used for rating the severity of PTSD symptoms. Scores range from 0-80 with higher scores indicating greater PTSD severity

    3. Change in CAPS-5 scores from baseline to post-treatment for the IPT treatment group [Baseline, 15 weeks]

      The CAPS-5 is used for rating the severity of PTSD symptoms. Scores range from 0-80 with higher scores indicating greater PTSD severity

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • English-speaking

    • Military Sexual Trauma (MST) survivors, with MST defined as actual or threatened sexual violence, from Vietnam era to current Operation Iraqi Freedom/Operation Enduring Freedom/Operation New Dawn

    • Diagnosed with PTSD consequent to MST, with a minimum CAPS score > 40

    • Medically stable at time of study enrollment (for persons with chronic injuries and that any disability present does not prevent attendance of weekly outpatient therapy sessions)

    • Ability to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments

    • Stable on psychotropic medication for the prior 60 days

    Exclusion Criteria:
    • Lifetime or current diagnosis of schizophrenia or other psychotic disorder, bipolar disorder

    • Participation in a clinical trial or concurrent evidence-based treatment for MST-related psychiatric conditions or PTSD during the previous 3 months

    • Current evidence of significant unstable medical illness or organic brain impairment such that the patient could not attend sessions regularly or complete assessments

    • Patients who in the investigator's judgment pose a current homicidal or suicidal risk

    • Current or history of substance dependence in the past 90 days.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Weill Cornell Medicine New York New York United States 10065

    Sponsors and Collaborators

    • Weill Medical College of Cornell University
    • United States Department of Defense

    Investigators

    • Principal Investigator: JoAnn Difede, PhD, Weill Medical College of Cornell University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Weill Medical College of Cornell University
    ClinicalTrials.gov Identifier:
    NCT03803332
    Other Study ID Numbers:
    • 1409015511
    • W81XWH-16-R-BAA1
    First Posted:
    Jan 14, 2019
    Last Update Posted:
    Oct 28, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Weill Medical College of Cornell University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 28, 2021